Boston Scientific Corp.

Boston Scientific Corp. has hit a new 52-week low, with its stock price declining significantly over the past year. The company, with a market capitalization of approximately USD 121.9 billion, operates in the retailing industry and exhibits a price-to-earnings ratio of 36.00 and a return on equity of 13.88%.

Boston Scientific Corp. has reached a new 52-week low, reflecting a significant decline in its stock performance over the past year. The company, with a market capitalization of approximately USD 121.9 billion, maintains a P/E ratio of 36.00 and a low debt-to-equity ratio of 0.39, indicating solid financial health.

Boston Scientific Corp. saw its stock decline significantly today, contrasting with a slight increase in the S&P 500. Over the past month, the company has faced challenges, with a notable year-to-date drop. Despite this, it holds a strong market position and demonstrates healthy long-term growth metrics.

Boston Scientific Corp. faced a significant stock decline today, contrasting with the S&P 500's gains. Over the past month, the company has seen a notable drop, with annual performance down substantially. Despite these challenges, Boston Scientific has shown long-term growth, with strong sales and solid financial metrics.

Boston Scientific Corp. saw a notable increase in stock performance on April 22, 2026, reaching an intraday high. Despite facing year-to-date and one-year declines, the company has shown resilience over three years. Key financial metrics include strong operating cash flow and net sales, underscoring its operational capabilities.

Boston Scientific Corp. experienced a strong opening, significantly outperforming the S&P 500. The company reported quarterly net sales of USD 5,061 million, with a 12.73% annual growth rate and robust operating cash flow of USD 4,285 million. Its fundamentals remain solid, despite some bearish technical indicators.

Boston Scientific Corp. has reached a new 52-week low, reflecting a challenging year with a notable decline in stock performance. The company, with a market capitalization of USD 121.9 billion, has a P/E ratio of 36.00 and a low debt-to-equity ratio of 0.39, indicating financial stability.

Boston Scientific Corp. has reached a new 52-week low of USD 60.59, reflecting a one-year decline of 20.85%. The company, with a market capitalization of approximately USD 121.94 billion, has a P/E ratio of 36.00 and a debt-to-equity ratio of 0.39, indicating moderate debt levels.

Boston Scientific Corp. has reached a new 52-week low, reflecting a challenging year with a significant stock decline. The company, valued at approximately USD 121.9 billion, has a P/E ratio of 36.00 and a debt-to-equity ratio of 0.39, indicating a conservative leverage approach. Its return on equity stands at 13.88%.

Boston Scientific Corp. has hit a new 52-week low, with a notable decline in its stock price and a 1-year performance decrease. The company, categorized as large-cap with a market capitalization of USD 130,304 million, faces challenges in the current market, contrasting with the S&P 500's strong performance.

Boston Scientific Corp. has reached a new 52-week low, reflecting a challenging year with a decline in performance compared to the S&P 500. The company has a market capitalization of USD 130,304 million, a P/E ratio of 69.00, and a return on equity of 13.88%, indicating effective management.

Boston Scientific Corp. has recently revised its market evaluation, with its stock priced at $72.99, reflecting a slight increase. Despite facing a 30.29% decline over the past year, the company has shown resilience with significant returns of 52.63% over three years and 84.60% over five years.

Boston Scientific Corp. has reached a new 52-week low, reflecting a notable decline in its stock price over the past year, contrasting with the S&P 500's gains. The company, with a market capitalization of USD 130 billion, has a high P/E ratio and a low debt-to-equity ratio, indicating its financial positioning.

Boston Scientific Corp. faced a significant decline today, contrasting with the S&P 500's smaller decrease. Over the past month, the stock has dropped notably, while year-over-year performance shows a substantial decline. Despite recent challenges, the company has demonstrated strong long-term growth and solid financial metrics.

Boston Scientific Corp. has recently revised its evaluation amid current market dynamics. The stock price is $76.85, reflecting a slight increase. Over the past year, the company has faced a significant decline, contrasting with broader market performance. Mixed technical indicators suggest challenges ahead, yet long-term returns remain strong.

Boston Scientific Corp. has seen a significant increase in its stock price today, contrasting with the broader market's performance. Despite recent fluctuations, the company has demonstrated strong long-term growth, with notable increases in net sales and operating cash flow, reflecting its solid financial health and market position.

Boston Scientific Corp. has adjusted its valuation amid a challenging year, with a stock performance decline of 28.83%. Key financial metrics include a P/E ratio of 69 and a price-to-book value of 7.83. Despite difficulties, the company maintains a competitive position relative to peers in the retailing sector.

Boston Scientific Corp. has shown significant growth, with a notable intraday high and strong weekly and monthly performance. The company has outperformed the S&P 500 in annual and year-to-date gains. Key financial metrics indicate robust sales growth and high institutional investor support, reflecting its resilience in the industry.

Boston Scientific Corp. has recently encountered a Death Cross, indicating a potential shift in market sentiment. While technical indicators suggest a bearish trend, the stock has shown resilience with a one-year performance slightly outperforming the S&P 500. Mixed signals from various indicators suggest a complex market position.